were first reported by Ryan, but no details of the case were given3; and Rubino and Jackson described a patient who developed confusion and paranoia while receiving tocainide but only after the addition of propranolol to the treatment regimen.5
Hypocalcaemia in pernicious anaemia
We describe a previously unreported association of hypocalcaemia and pernicious anaemia. After an initial observation in an index case, a group of patients who had previously been found to have pernicious anaemia were investigated retrospectively.
Case report, methods, and results
A 32 year old man presented with a six month history of malaise, weakness, and loss of 3-2 kg; he denied abdominal pain and steatorrhoea. On examination he was seen to be pale but had no other physical signs. Haemoglobin concentration was 8-4 g/dl, mean corpuscular volume was 110 fl (110 jtm), and platelet and white cell counts were normal, although the blood film contained hypersegmented neutrophils. Serum calcium concentration was 2-1 mmol/l (8-6 mg/100 ml) and albumin 38 g/l. Alkaline phosphatase activity and other liver function values, phosphate, iron and iron binding capacity, folate, xylose tolerance, and three day faecal fat excretion, were all within normal ranges. Vitamin B,2 concentration was <50 pg/l with an abnormal Schilling test part I (< 7% of an oral dose of radioactive vitamin B12 alone excreted in the urine in 24 hours) but normal Schilling test part II.
Bone marrow aspirate confirmed a megaloblastic picture. After six weeks of treatment with hydroxycobalamin the haematological indices and film were normal and the serum calcium concentration 2-3 mmol/l (9-0 mg/100 ml) and albumin 40 g/l.
Serum calcium concentrations in patients reviewed six months to seven years after diagnosis of pernicious anaemia the concentration was less than 2-2 mmol/l (8.6 mg/100 ml). Twenty two of these patients were contacted (six months to seven years after initial presentation) and a full blood count and multichannel analysis repeated. All 22 patients were haematologically and biochemically normal except for their calcium values (see table) .
Comment
Our group of patients with pernicious anaemia had significant hypocalcaemia as compared with an age and sex matched control group, the cause of which was uncertain. Although treatment was associated with a significant rise in serum corrected calcium values, the group was still significantly hypocalcaemic as compared with the control group. The index patient had no signs, symptoms, or biochemical abnormalities of malabsorption or osteomalacia, and all patients studied had normal serum phosphate and alkaline phosphatase activities, making these diagnoses unlikely.
Hypoparathyroidism is a possible explanation, but rare, although an autoimmune aetiology might explain this and the pernicious anaemia. Chronic hypergastrinaemia occurs in pernicious anaemia but the concentration is usually not high enough to affect calcium metabolism by stimulating secretion of calcitonin. Two months after the accident the serum calcium concentration increased above 3 mmol/l (12 mg/100 ml) (figure); he developed anorexia, malaise, vomiting, and abdominal pains, and his general condition declined. His daily fluid intake was increased (3 1/day), and frusemide was given; the serum calcium concentration and abdominal complaints remained unchanged. Treatment with salcatonin (Miacalcic), 100-200 MRC units/24 h intramuscularly or subcutaneously, was started, and the serum calcium concentration decreased to 2-5 mmol/l (10 mg/100 ml) but then increased again. Sodium acid phosphate was given by mouth; symptoms resolved, and near normal serum calcium concentrations were established.
Four months after the start of the combined treatment his symptoms and hypercalcaemia recurred, serum calcium concentrations exceeding 3 mmol/l (12 mg/100 ml) being recorded. It was then decided to try disodium etidronate (Didronel) 5 mg/kg/24 h by mouth; salcatonin and sodium acid phosphate were stopped. Within a month he had essentially normal serum calcium concentrations, his gastrointestinal complaints had resolved completely, and he began to gain weight. Two months after disodium etidronate was stopped he still had normal serum calcium concentrations.
CASE 2
The patient was a 17 year old healthy man with normal serum calcium concentrations. Three months after he was immobilised because of a fracture at the level of C6-7 hypercalcaemia of 3-1 mmol/l (12-4 mg/100 ml) was noted. Disodium etidronate 5 mg/kg/24 h was given by mouth. The serum calcium concentration returned to normal in 10 days, and he was mobilised. Fluid intake was 3 1/24 h, but no other measures were undertaken to lower the serum calcium concentration.
OTHER FINDINGS
Urinary hydroxyproline concentrations were raised in both patients and did not change during treatment with disodium etidronate. No side effects of disodium etidronate were noted.
Comment
In both these patients serum calcium concentrations returned to normal within one month after the start of treatment with disodium etidronate. Interestingly, no changes occurred in urinary hydroxyproline excretion, a finding reported previously with treatment with disodium etidronate and of unknown importance.3 The possibility that the doses of the drug used in our patients were too low does not seem likely.
Treatment with disodium etidronate confers a risk of developing osteomalacia, and long term use of high doses should be avoided. Disodium clodronate and disodium aminohydroxypropylidenediphosphonate show a lesser tendency to cause osteomalacia.4 Disodium clodronate prevents bone mineral loss and hypercalcaemia in paraplegic patients, but has now been abandoned because of potentially cancerigenic effects.
In conclusion, we suggest that disodium etidronate (5 mg/kg/24 h for less than six months) or, preferably, disodium aminohydroxypropylidenediphosphonate be used in hypercalcaemia due to im-
